A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins

Journal of Theoretical Biology

Volumn 386, Issue , 2015, Pages 89-104

  Suryawanshi, Gajendra W ^a,b   Hoffmann, Alexander ^a,b  

^a University of California San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age structured models; Combination therapy; Host restriction factors; Hypermutations; Reproductive ratio

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BONE MARROW STROMAL CELL ANTIGEN 2; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VPU PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRAL PROTEIN;

ENZYME ACTIVITY; GENOME; HOST; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INFECTIOUS DISEASE; MUTATION; NUMERICAL MODEL; PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CALCULATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INHIBITION CONSTANT; INHIBITION KINETICS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MICROBIAL POPULATION DYNAMICS; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION; SENSITIVITY ANALYSIS; SIMULATION; STEADY STATE; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG POTENTIATION; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; VIRAL LOAD; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS REPLICATION;

EID: 84942858449     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2015.08.032     Document Type: Article

References (57)

1. Alce T.M., Popik W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 2004, 279(August (33)):34083-34086. URL http://dx.doi.org/10.1074/jbc.C400235200.
2. Althaus C.L., de Boer R.J. Intracellular transactivation of HIV can account for the decelerating decay of virus load during drug therapy. Mol. Syst. Biol. 2010, 6:348. URL http://www.ncbi.nlm.nih.gov/pubmed/20160709.
3. Althaus C.L., de Vos A.S., de Boer R.J. Reassessing the human immunodeficiency virus type 1 life cycle through age-structured modeling. life span of infected cells, viral generation time, and basic reproductive number, R0. J. Virol. 2009, 83(15):7659-7667. URL http://www.ncbi.nlm.nih.gov/pubmed/19457999.
4. Apolonia L., Schulz R., Curk T., Rocha P., Swanson C.M., Schaller T., Ule J., Malim M.H. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1. PLoS Pathog. 2015, 11(January (1)):e1004609. URL http://dx.doi.org/10.1371/journal.ppat.1004609.
5. Berenbaum M.C. What is synergy?. Pharmacol. Rev. 1989, 41(2):93-141.
6. Bishop K.N., Holmes R.K., Sheehy A.M., Malim M.H. APOBEC-mediated editing of viral RNA. Science 2004, 305(5684):645. URL http://www.ncbi.nlm.nih.gov/pubmed/15286366.
7. Brass A.L., Dykxhoorn D.M., Benita Y., Yan N., Engelman A., Xavier R.J., Lieberman J., Elledge S.J. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008, 319(5865):921-926. URL http://www.ncbi.nlm.nih.gov/pubmed/18187620.
8. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58(3):621-681. URL http://www.ncbi.nlm.nih.gov/pubmed/16968952.
9. Chou T.-C., Talalay P. Analysis of combined drug effects. a new look at a very old problem. Trends Pharmacol. Sci. 1983, 4:450-454.
10. Cocka L.J., Bates P. Identification of alternatively translated tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog. 2012, 8(9):e1002931.
11. Conticello S.G., Harris R.S., Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral dna deaminase apobec3g. Curr. Biol. 2003, 13(22):2009-2013. URL http://www.ncbi.nlm.nih.gov/pubmed/14614829.
12. Dixit N.M., Markowitz M., Ho D.D., Perelson A.S. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir. Ther. 2004, 9:2. URL http://www.ncbi.nlm.nih.gov/pubmed/15134186.
13. Dube M., Paquay C., Roy B.B., Bego M.G., Mercier J., Cohen E.A. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface. Traffic 2011, 12(12):1714-1729. URL http://www.ncbi.nlm.nih.gov/pubmed/21902775.
14. Dussart S., Douaisi M., Courcoul M., Bessou G., Vigne R., Decroly E. APOBEC3G ubiquitination by Nedd4-1 favors its packaging into HIV-1 particles. J. Mol. Biol. 2005, 345(January (3)):547-558. URL http://dx.doi.org/10.1016/j.jmb.2004.10.067.
15. Fauci A.S., Folkers G.K., Dieffenbach C.W. HIV-AIDS. much accomplished, much to do. Nat. Immunol. 2013, 14(11):1104-1107. URL http://www.ncbi.nlm.nih.gov/pubmed/24145780.
16. Gilchrist M.A., Coombs D., Perelson A.S. Optimizing within-host viral fitness. infected cell lifespan and virion production rate. J. Theor. Biol. 2004, 229(2):281-288. URL http://www.ncbi.nlm.nih.gov/pubmed/15207481.
17. Gottlinger H.G., Dorfman T., Cohen E.A., Haseltine W.A. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. USA 1993, 90(15):7381-7385. URL http://www.ncbi.nlm.nih.gov/pubmed/8346259.
18. Guedj J., Dahari H., Rong L., Sansone N.D., Nettles R.E., Cotler S.J., Layden T.J., Uprichard S.L., Perelson A.S. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl. Acad. Sci. USA 2013, 110(10):3991-3996. URL http://www.ncbi.nlm.nih.gov/pubmed/23431163.
19. Hache G., Mansky L.M., Harris R.S. Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev. 2006, 8(3):148-157. URL http://www.ncbi.nlm.nih.gov/pubmed/17078485.
20. Hosseini I., mac Gabhann F. Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy. PLoS Comput. Biol. 2012, 8(2):e1002371. URL http://www.ncbi.nlm.nih.gov/pubmed/22346743.
21. Hosseini I., mac Gabhann F. APOBEC3G-augmented stem cell therapy to modulate HIV replication. a computational study. PLoS One 2013, 8(5):e63984. URL http://dx.doi.org/10.1371/journal.pone.0063984.
22. Jern P., Russell R.A., Pathak V.K., Coffin J.M. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 2009, 5(4):e1000367. URL http://www.ncbi.nlm.nih.gov/pubmed/19343218.
23. Khan M.A., Kao S., Miyagi E., Takeuchi H., Goila-Gaur R., Opi S., Gipson C.L., Parslow T.G., Ly H., Strebel K. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 2005, 79(May (9)):5870-5874. URL http://dx.doi.org/10.1128/JVI.79.9.5870-5874.2005.
24. Kirschner D., Webb G.F. A model for treatment strategy in the chemotherapy of AIDS. Bull. Math. Biol. 1996, 58(2):376-390. URL http://www.ncbi.nlm.nih.gov/pubmed/8713663.
25. Konig R., Zhou Y., Elleder D., Diamond T.L., Bonamy G.M., Irelan J.T., Chiang C.Y., Tu B.P., de Jesus P.D., Lilley C.E., Seidel S., Opaluch A.M., Caldwell J.S., Weitzman M.D., Kuhen K.L., Bandyopadhyay S., Ideker T., Orth A.P., Miraglia L.J., Bushman F.D., Young J.A., Chanda S.K. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008, 135(1):49-60. URL http://www.ncbi.nlm.nih.gov/pubmed/18854154.
26. Malim M.H., Bieniasz P.D. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2012, 2(5):a006940.
27. Malim M.H., Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3(6):388-398.
28. Mangeat B., Gers-Huber G., Lehmann M., Zufferey M., Luban J., Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-trcp2-dependent degradation. PLoS Pathog. 2009, 5(9):e1000574. URL http://www.ncbi.nlm.nih.gov/pubmed/19730691.
29. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424(6944):99-103. URL http://www.ncbi.nlm.nih.gov/pubmed/12808466.
30. Matsui M., Shindo K., Izumi T., Io K., Shinohara M., Komano J., Kobayashi M., Kadowaki N., Harris R.S., Takaori-Kondo A. Small molecules that inhibit Vif-induced degradation of APOBEC3G. Virol. J. 2014, 11:122. URL http://www.ncbi.nlm.nih.gov/pubmed/24986077.
31. McNatt M.W., Zang T., Bieniasz P.D. Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog. 2013, 9(4):e1003299. URL http://www.ncbi.nlm.nih.gov/pubmed/23633949.
32. Mi Z., Wang X., He Y., Li X., Ding J., Liu H., Zhou J., Cen S. A novel peptide to disrupt the interaction of BST-2 and Vpu. Biopolymers 2014, 102(3):280-287. URL http://www.ncbi.nlm.nih.gov/pubmed/24676648.
33. Mohammadi P., Desfarges S., Bartha I., Joos B., Zangger N., Munoz M., Gunthard H.F., Beerenwinkel N., Telenti A., Ciuffi A. 24 hours in the life of HIV-1 in a T cell line. PLoS Pathog. 2013, 9(1):e1003161. URL http://www.ncbi.nlm.nih.gov/pubmed/23382686.
34. Neil S.J., Sandrin V., Sundquist W.I., Bieniasz P.D. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007, 2(3):193-203. URL http://www.ncbi.nlm.nih.gov/pubmed/18005734.
35. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451(7177):425-430. URL http://www.ncbi.nlm.nih.gov/pubmed/18200009.
36. Nelson P.W., Gilchrist M.A., Coombs D., Hyman J.M., Perelson A.S. An age-structured model of HIV infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells. Math. Biosci. Eng. 2004, 1(2):267-288. URL http://www.ncbi.nlm.nih.gov/pubmed/20369971.
37. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M., Ho D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387(6629):188-191. URL http://www.ncbi.nlm.nih.gov/pubmed/9144290.
38. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo. virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271(5255):1582-1586. URL http://www.ncbi.nlm.nih.gov/pubmed/8599114.
39. Perez-Caballero D., Zang T., Ebrahimi A., McNatt M.W., Gregory D.A., Johnson M.C., Bieniasz P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139(3):499-511. URL http://www.ncbi.nlm.nih.gov/pubmed/19879838.
40. Pillai S.K., Abdel-Mohsen M., Guatelli J., Skasko M., Monto A., Fujimoto K., Yukl S., Greene W.C., Kovari H., Rauch A., Fellay J., Battegay M., Hirschel B., Witteck A., Bernasconi E., Ledergerber B., Gunthard H.F., Wong J.K., Swiss H.I.V.C.S. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc. Natl. Acad. Sci. USA 2012, 109(8):3035-3040. URL http://www.ncbi.nlm.nih.gov/pubmed/22315404.
41. Rong L., Feng Z., Perelson A. Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy. SIAM J. Appl. Math. 2007, 67(3):731-756. URL http://epubs.siam.org/doi/abs/10.1137/060663945.
42. Rong, L., Feng, Z., Perelson, A., 2008. Mathematical modeling of HIV-1 infection and drug therapy. In: Applied Optimization, vol. 102. Springer Berlin Heidelberg, pp. 87-131 (Book Section 3).
43. Rong L., Guedj J., Dahari H., Coffield D.J.J., Levi M., Smith P., Perelson A.S. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput. Biol. 2013, 9(3):e1002959. URL http://www.ncbi.nlm.nih.gov/pubmed/23516348.
44. Rong L., Perelson A.S. Modeling HIV persistence, the latent reservoir, and viral blips. J. Theor. Biol. 2009, 260(2):308-331.
45. Rong L., Perelson A.S. Modeling latently infected cell activation. viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput. Biol. 2009, 5(10):e1000533.
46. Schäfer A., Bogerd H.P., Cullen B.R. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 2004, 328(October (2)):163-168. URL http://dx.doi.org/10.1016/j.virol.2004.08.006.
47. Schmidt S., Fritz J.V., Bitzegeio J., Fackler O.T., Keppler O.T. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. mBio 2011, 2(3):e00036-e00311. URL http://www.ncbi.nlm.nih.gov/pubmed/21610122.
48. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 2003, 9(11):1404-1407. URL http://www.ncbi.nlm.nih.gov/pubmed/14528300.
49. Soros V.B., Yonemoto W., Greene W.C. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 2007, 3(February (2)):e15. URL http://dx.doi.org/10.1371/journal.ppat.0030015.
50. Stafford M.A., Corey L., Cao Y., Daar E.S., Ho D.D., Perelson A.S. Modeling plasma virus concentration during primary HIV infection. J. Theor. Biol. 2000, 203(3):285-301. URL http://www.ncbi.nlm.nih.gov/pubmed/10716909.
51. Thangavelu P.U., Gupta V., Dixit N.M. Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection. Virology 2014, 449:224-228. URL http://www.ncbi.nlm.nih.gov/pubmed/24418556.
52. Tokarev A.A., Munguia J., Guatelli J.C. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J. Virol. 2011, 85(1):51-63.
53. van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3(4):245-252. URL http://www.ncbi.nlm.nih.gov/pubmed/18342597.
54. Wang T., Tian C., Zhang W., Luo K., Sarkis P.T.N., Yu L., Liu B., Yu Y., Yu X.-F. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 2007, 81(December (23)):13112-13124. URL http://dx.doi.org/10.1128/JVI.00892-07.
55. Xu H., Chertova E., Chen J., Ott D.E., Roser J.D., Hu W.S., Pathak V.K. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 2007, 360(2):247-256. URL http://www.ncbi.nlm.nih.gov/pubmed/17126871.
56. Zhou H., Xu M., Huang Q., Gates A.T., Zhang X.D., Castle J.C., Stec E., Ferrer M., Strulovici B., Hazuda D.J., Espeseth A.S. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008, 4(5):495-504. URL http://www.ncbi.nlm.nih.gov/pubmed/18976975.
57. Zuo T., Liu D., Lv W., Wang X., Wang J., Lv M., Huang W., Wu J., Zhang H., Jin H., Zhang L., Kong W., Yu X. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. J. Virol. 2012, 86(10):5497-5507. URL http://www.ncbi.nlm.nih.gov/pubmed/22379088.